Online pharmacies will now have to employ stricter checks to stop people who are already a healthy weight or have a history ...

The prevalence of obesity in India was lower than in other countries but now it's increasing, Rachel Batterham, senior vice ...

Learn how managing high blood pressure and high cholesterol keeps your heart health in check and helps prevent liver issues such as MASH.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Wonder drugs’ like Ozempic, hailed by celebrities and some medics as a cure for an ever-mounting list of conditions, most notably obesity and diabetes, have started to appear in darker headlines ...

As many as 17% of men and 34% of women in the United States suffer from sleep apnea, and the numbers are increasing. KYW ...

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...

The agency has approved a four-dose version of the drug, called Mounjaro KwikPen, which provides a month’s course of GLP-1 and GIP agonist tirzepatide ... high blood pressure, high cholesterol ...

Weight-loss jabs such as Ozempic are being hailed as a potential breakthrough in the fight against obesity. Demand, fuelled ...

One of the most exciting developments in diabetes treatment is the use of new medications that help control blood sugar in ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...